Advinus Sees Diabetes Molecule Breakthrough In Six Months

The Tata Group-promoted Advinus Therapeutics is expecting a breakthrough for a diabetes molecule in about six months. The company is likely to license it to other companies, according to Tata Sons Executive Director R Gopalakrishnan.

Advinus has already completed the first-stage development of the molecule and is set to initiate talks with pharma companies for further drug trials, he added. At present, five full-discovery programmes are on for internal research.

Advinus has a collaboration with Merck (USA) for drug discovery in the area of metabolic diseases.

The company has a drug discovery centre in Pune that focuses on diabetes, obesity, lipid disorders, inflammatory diseases and neglected diseases like dengue and malaria. Its Bangalore centre has a collaboration with DNDi (Drugs for Neglected), he said.

Advertisements
Post a comment or leave a trackback: Trackback URL.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: